Terapêuticas aplicadas à doença de graves no HUAC: uma análise de custo-benefício.

Abstract

Graves' disease is the most common etiology of hyperthyroidism, and because it has severe cardiovascular consequences, it is necessary to institute the most cost-effective therapy. The objective of this study is to highlight the profile of patients treated with GD at HUAC and to evaluate the cost-benefit of therapies employed to treat this condition considering this profile. The present study was based on the review of hospitalization records performed at HUAC between 2012 and 2018, under ICD-10 E05 and variants. 58.4% of the patients had low education, 35.3% lived in rural areas, 35.3% had no access to basic sanitation; 63.6% had irregular use of medications, 71.4% had loss of follow-up, 44.7% readmitted and 58.8% achieved remission, of which 70.6% after radioiodine. The total cost of the treatments of 8 selected patients was R$ 59,856.73, which would early treat with radioiodine 100% of new cases of DG in CG each year. Comparing the cost-benefit ratio between the two therapies, it is noticeable that if definitive radioiodine therapy were employed early, the expense would be considerably lower. Considering the socioeconomic profile of most of the population served by the SUS, early radioiodine therapy should be considered in such patients because it is free and easily adhered to.